Yes , my blurry eyed morning self meant to say.
Potency assay approval will lead to manufacturing at scale.
That manufacturing at scale creates a valuation.
That valuation may be used in calculations of a takeover offer.
I expect Novartis will swallow Rem-L whole, if not all of Mesoblast.
Reg
Ann: CEO Presentation to 2021 Annual General Meeting, page-55
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 97.5¢ | 95.5¢ | $1.174M | 1.209M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 54615 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 70465 | 14 |
View Market Depth
| Last trade - 10.54am 27/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |